SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the launch of their fibromyalgia drug, TONMYA, nears, with discussions focusing on its potential impact and market penetration. The community is debating the significance of institutional ownership and analyzing the company's financial health in relation to the upcoming commercial execution. Anticipation of revenue generation and a possible short squeeze are also fueling interest.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending due to recent earnings report indicating a 50% YoY revenue increase and record customer growth, although margins were pressured by higher delivery expenses. Community discussion revolves around the impressive revenue numbers and store expansion, with some expressing concern over margin decline and a lack of updates regarding a potential US relisting. Overall, while growth is undeniable, the sustainability of margins and potential catalysts like relisting are key talking points.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending after Berkshire Hathaway disclosed a $4.3 billion stake, fueling optimism and driving shares up. The community is discussing whether this move signals a broader shift in Warren Buffett's investment strategy towards tech and AI, while others debate the valuation and potential for further gains. This news coincides with Alphabet's ongoing investments in data centers to support cloud and AI initiatives.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Zymeworks Inc

ZYME is trending following positive Phase 3 trial results for their cancer treatment Ziihera, developed in partnership with Jazz Pharmaceuticals. The community is discussing the potential impact on HER2-positive cancers and the financial implications for both ZYME and Jazz. Some traders caution about low trading volume and the potential risks of getting in now.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium ($SGML) is trending amid discussions around lithium prices, production capacity, and potential takeover scenarios. Community members are analyzing the impact of fluctuating lithium prices on the company's future earnings and debating whether recent price movements signal a potential sector recovery, while also noting insider buying activity. Some traders discuss technical indicators and potential short squeezes, while cautioning of continued volatility given recent price action.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending amid buyout speculation, with community members debating the likelihood of a deal and potential premium. Discussions also involve insider selling and its impact on a possible acquisition. Despite the uncertainty, some believe GRND is undervalued, citing strong earnings and analyst price targets.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending due to positive developments in AI and robotics, including the unveiling of its 'Iron' humanoid robot, and expansion into new European markets. Community discussions revolve around the company's potential to surpass Tesla in robotics and its attractive valuation relative to its growth and innovation. Upcoming earnings are also a key point of interest, with investors anticipating strong results.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet (STRK) is trending as the community highlights its potential in BTCFi, staking, and overall ecosystem growth; a high percentage of the token supply being staked is a key factor. Some believe Starknet's technology, including the S-Two prover upgrade and focus on zero-knowledge proofs, positions it as a leader in Layer 2 scaling and privacy, drawing comparisons to Zcash (ZEC).

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

Wasatch Pharmaceutical Inc

Wasatch Pharmaceutical (WSHP) is trending due to its recent direct listing, with the community actively discussing potential entry points and watching for chart patterns. Some traders are pointing to the stock as a possible sympathy play, while others urge caution, calling it a scam.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata's stock is trending due to community speculation around a potential joint strategic partnership announcement with a market leader, possibly Palantir, before the end of the year. The optimism is fueled by positive sentiments shared from an institutional contact, analysis of Jack's language during the earnings call, and suggestive technical chart patterns. This buzz is further amplified by Innodata's growing presence in government AI and sovereign AI initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey...

Wedbush analyst David Nierengarten on Wednesday downgraded Generation Bio (GBIO) to ‘Neutral’ from ‘Outperform’ with a $7 price target after the company announced a strategic restructuring. Shares of the firm traded over 31% higher in Tuesday’s pre-market session.Generation Bio on Tuesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.generationbio.com/news-releases/news-release-details/generation-bio-announces-new-data-its-novel-ctlnp-delivery">announced</a> that it is evaluating strategic alternatives to maximize the value of its assets for shareholders. The company indicated that options include an acquisition, merger, business combination, sale of assets, or other strategic transactions, while noting that there is no assurance of the exploration resulting in a transaction. The company also said it is implementing a strategic restructuring in the meantime, expected to result in about 90% workforce reduction by the end of October.Based on the indefinite postponement of lead candidate selection and development plans, Wedbush said it is moving to the sidelines as the company seeks strategic alternatives.&nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GBIO">GBIO</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels. According to Stocktwits data, retail chatter around the stock rose 4,850% over the past 24 hours.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_7_06_39_AM_png_e6061d0735.webp" alt="GBIO's Sentiment Meter and Message Volume as of 7:06 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>GBIO's Sentiment Meter and Message Volume as of 7:06 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism on the stock’s value following the announcement.<stembedurl>https://stocktwits.com/Pennystockmadness/message/624911244</stembedurl>Another opined that they expect a massive sell-off on Wednesday after the earnings announcement.<stembedurl>https://stocktwits.com/MillionaireTrader555/message/624909244</stembedurl>Generation Bio on Tuesday reported second-quarter revenue of $765,000, down from the $4.09 million reported in the corresponding quarter of 2024, and below an analyst estimate of $2.51 million. Diluted loss per share came in at $3.12, versus an estimated loss of $2.85 per share.The company ended the quarter with cash, cash equivalents, and marketable securities of $141.4 million.GBOP stock is down by 62% this year and by about 84% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gildan-activewear-to-buy-hanes-brands-in-4-4-billion-deal/chrCJ0MRdBM">Gildan Activewear To Buy HanesBrands In $4.4B Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Generation Bio Stock Surged 31% Pre-Market Today – What’s Going On?

Generation Bio on Tuesday said that it is evaluating strategic alternatives to maximize the value of its assets for shareholders and implementing a strategic restructuring expected to result in a 90% reduction in workforce. 

Equity

Generation Bio on Tuesday said that it is evaluating strategic alternatives to maximize the value of its assets for shareholders and implementing a strategic restructuring expected to result in a 90% reduction in workforce. 


Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio (GBIO) delivered earnings and revenue surprises of -11.43% and -51.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +1.96% and +16.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

Analysts' Top Healthcare Picks: Generation Bio (GBIO), Bristol-Myers Squibb (BMY)

Analysts fell to the sidelines weighing in on Generation Bio (GBIO Research Report) and Bristol-Myers Squibb (BMY Research Report) with neutral...

Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases...

Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO - Get Free Report) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 1,270,000...

Generation Bio (GBIO, $3.7) price may drop as it broke higher Bollinger Band on Mar 27, 2024

This price move could be a signal that GBIO may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Generation Bio (GBIO, $3.33) entered Downtrend as Momentum indicator drops below 0 level on Mar 22, 2024

This indicator may be signaling that GBIO's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Generation Bio Co

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$5.42
Prev Close	$5.62
Open	$5.63
Dividend Yield	0.00%
50-Day Moving Average	$5.91
Beta	2.12
Avg. Volume	48,462.74
PE Ratio	-0.58

52-Week High	$16.79
52-Week Low	$3.00
Market Capitalization	$36.52M
EPS (Annual)	-$19.76
Price to Book	0.72
Revenue Per Employee	$172,973.91
Enterprise Value/EBITDA	N/A

GBIO
Generation Bio Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GBIO News

GBIOGeneration Bio Co